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Abstract
Current screening test for celiac disease involves blood test in centralized pathol-
ogy laboratories, typically performing enzyme-linked immune-sorbent assays 
(ELISA) to detect specific celiac disease antibodies. Most of the current available 
celiac disease antibody tests detect anti-gliadin (AGA), anti-endomysial (EMA), 
anti-transglutaminase (tTG), or deamidated gluten peptide (DGP) antibodies 
from serum or whole blood samples. It requires blood collection from untreated 
celiac patients, which is often invasive and inconvenient. There is a rapid growth in 
demand for noninvasive celiac tests for the early and fast diagnosis of celiac disease 
to help potential celiac patients obtain results and take corresponding actions. 
Over the last decade, several point-of-care tests (POCT) have been introduced to 
the market, but these tests have not been widely accepted by clinicians. Moreover, 
the 2009 NICE guideline CG 86 recommended that self-tests and/or POCT for 
celiac disease should not be used as a substitute for laboratory-based tests. Here, 
we provide a background on the evolution of POCT for celiac disease. We discuss 
general principle of operation for the known commercial kits as well as the use of 
various antigens and antibodies in different tests developed over the years. Finally, 
we discuss challenges for future research directions in celiac disease POCTs.
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1. Introduction
Celiac disease is defined as a lifelong condition as a result of ingestion of gluten 
among genetically susceptible people that can be relieved by the introduction of 
gluten-free diet; the condition relapses with gluten intake [1]. Recent studies show 
that it is prevalent around the world, covering from the western world, such as 
Europe and America, to Oceania, Africa, and Asia. The number of celiac sufferers 
increases, doubling its number every two decades [2]. The symptoms vary at a wide 
range, from flatulence, constipation, anorexia, irregular bowel habits, and irritabil-
ity to numbness in limbs, foggy mind, diarrhea, and depression [3]. Therefore, it 
is hard to recognize the condition and deliver the diagnosis. In fact, almost 90% of 
celiac patients remain undiagnosed, due to the nonspecific or absent symptoms over 
a long period [4]. Thereby, it is of paramount significance to achieve the early-stage 
diagnosis of celiac disease that can lead to improving the patients’ quality of life.
The current gold standard of celiac disease diagnosis, which has been also devel-
oped in a much earlier period, is to observe the small intestine atrophy obtained 
through biopsy [1]. This process is highly invasive, time-consuming, and inconve-
nient to both patients and clinicians.
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Over the last several decades, researchers have found that the concentration 
of some certain antibodies circulating in celiac patients’ body increased, and the 
detection of celiac disease can be achieved with the detection of these antibodies. 
In fact, the surface of mucosa represents the major targeted sites when foreign 
antigens attack the body [5]. Plausibly, 80% of all cells producing immunoglobulin 
(IgG) in the human body are in small bowel mucosa, which also produces the 
dimers of IgA [6]. Therefore, the antibodies of celiac disease among untreated 
patients are located in the mucosal surface [7], as extracellular deposit, some 
present in jejunal juice [8], and most in the intestine [9, 10]. For untreated celiac 
patients, the additional generation of antibodies leads to an increase of antibodies 
specific to celiac disease (IgA− class), most of which can be found in the circulat-
ing blood and some other bodily fluids. Among all the celiac-specific antibodies, 
anti-reticulin (ARA), anti-jejunal (JEA), endomysial (EMA), and tissue transglu-
taminase antibodies (tTG) are among the patients’ own endogenous biomolecules 
that form as a result of immune response to antigen in the intestine, whereas 
anti-gliadin antibody (AGA) and deamidated gliadin peptide antibody (DGP-Ab) 
are formed directly against dietary gliadin [11].
Over the years, the detection of the celiac-related antibodies has shown promis-
ing results, and whole blood- or serum-based pathology tests are regularly used 
for screening for celiac disease. Typically, screening for celiac disease includes tests 
for identification of titers for AGA and/or anti-tTG antibodies, and most of these 
tests are based on enzyme-linked immunoassays (ELISA). Even though the method 
of ELISA can reach a high sensitivity and specificity, these tests cannot be used 
on their own in the process of celiac disease diagnosis. Furthermore, pathology 
tests are typically confined to centralized laboratories, where expert personnel is 
required, leading to slow- and high-cost detections. Thereby, it is not suitable for 
the use outside hospitals, such as clinical offices or home settings, leaving a high 
number of undiagnosed celiac cases, especially when their symptoms are not obvi-
ous or do not affect their normal life. Thus, simple and rapid detection methods are 
in high demand to be developed.
Fast, accurate, and noninvasive early diagnosis methods and/or devices are 
needed to achieve the detection of celiac disease with high sensitivity and specificity, 
especially facing the rapid increasing number of celiac patients. Over the last decade, 
several point-of-care blood tests have been developed and applied for celiac diseases 
screening. The most prominent tests are Simtomax® Blood Drop system (Augurix SA, 
Switzerland) and Biocard™ celiac test (AniBiotech®, Finland), lateral flow immuno-
assays that detect anti-tTG and/or anti-deamidated gliadin peptide antibodies.
Lateral flow test, also called lateral flow immunoassay or test strip, has been 
widely and commercially used in the rapid detection of many diseases and condi-
tions, such as HIV, illicit drugs, and early pregnancy [12]. In the following sections, 
we will discuss and compare several commercial kits available as POCT devices for 
celiac disease. The principle of lateral flow test is outlined in the next section.
2. Lateral flow immunoassays
Lateral flow immunoassay is a simple immunochromatography technology that 
has successfully applied for rapid diagnostic testing [12, 13]. It typically made of 
nitrocellulose or paper-based porous membrane that makes it ideal to fabricate 
low-cost devices with little maintenance requirements. Porous membrane enables 
the separation, capture, and recognition of the target analytes. In addition, porous 
nature of the material facilitates movement of fluids, such as a whole blood, serum, 
or urine, by means of capillary action with no external force required.
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There are several types of lateral flow assays available, but the most popular is 
the capture format. There are two types of capture: “sandwich” and competitive 
capture [13].
Overall, lateral flow immunoassay consists of four parts: sample pad, conjugate 
pad, nitrocellulose membrane (test line and control line labeled on it), and absor-
bent pad (also called wicking; Figure 1). Typically, fluid sample (blood, serum, 
urine, saliva) is added onto sample pad. Through the capillary action, the liquid 
moves to the conjugate pad, where preloaded recognition element (conjugated 
nanoparticles or colored reagent) is imbedded. The sample and the recognition 
reagent react commonly through antigen-antibody interaction. The sample together 
with the recognition element continues flowing within nitrocellulose membrane 
toward test and control lines. Depending on the type of a capture, sandwich or 
competitive, the test line would show a colorful line or disappear, respectively. 
Control line always shows colorful signal to indicate the correct functionality of the 
test. Absorbent pad function is to collect all the unreacted reagents as well as excess 
of liquids.
Lateral flow immunoassay for celiac disease is typically used to detect antibod-
ies, such as anti-tTG, anti-DGP, and AGA antibodies from the whole blood or serum 
in a sandwich type of detection [14–18]. Preloaded reagent can be gold nanopar-
ticles or dye conjugated to antigens, such as transglutaminase, deamidated gliadin 
peptides, and gliadin protein fragments. The detection of celiac disease-related 
antibodies will present as color test line that can be usually seen by the naked eye.
Lateral flow test or strip test is often used as a point-of-care test (POCT) due 
to its high specificity, visual color confirmation, and, especially, because of no 
additional instrumentation is required. In fact, most of the current commercial 
POCTs for celiac disease are based on lateral flow assay to detect antibodies. In the 
following section, we will discuss and make a comparison among commercial kits 
available together with the outlining principles of POCT device for celiac disease.
3. Point-of-care tests for celiac disease
3.1 Current commercial point-of-care tests
One of the most widely used commercial kits for celiac disease detection is 
the new generation of Biocard™ celiac test (AniBiotech®, Vantaa, Finland). In 
this commercial kit, lateral flow method was utilized to detect human anti-tTG 
IgA antibodies from a whole blood. Gold-labeled anti-human IgA antibodies are 
Figure 1. 
Schematic representation of lateral flow immunoassay in a capture format. Various important parts of the test 
are identified as sample, conjugate, and absorbent pads, nitrocellulose membrane with test and control lines.
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prefixed on the conjugate pad, protein that binds to tTG antigen on the test line and 
anti-mouse IgG antibody on the control line [19].
The procedure is as follows: first, a drop of whole blood is taken from a finger 
prick, and then, the assumption is if the blood sample contains anti-tTG antibody, 
it will complex with liberated self-tTG found on hemolyzed red blood cells. Then 
the complex will flow to the conjugated pad due to the capillary force, forming a 
larger complex with anti-human IgA labeled on gold colloids. The larger aggregate 
is then recognized and captured by the tTG binding protein on the test line, and the 
red color will appear. The excess gold-labeled anti-IgA antibodies migrate further 
to control line, combining with anti-mouse IgG antibodies, which is prefixed on the 
control line, producing another red line (Figure 2). Both red lines represent positive 
result; only one red line in the control line means negative. If neither of the lines 
turns red, it means the subject is IgA deficient, or the test did not function properly. 
Usually the result can be viewed within 5–10 min; positive result can even appear 
after 2 min.
Since the Biocard™ celiac test has been made available on the market, a consid-
erable number of papers have evaluated its sensitivity and specificity. Though the 
reported sensitivity and specificity vary in a wide range, most of them are around 
90%, where some can reach as high as 93 and 94% for sensitivity and specificity, 
respectively [19–24]. However, this result is slightly lower than laboratory-based 
celiac disease test (more than 95%); therefore, this commercial kit can be only used 
for screening for celiac disease, but not for diagnosis. Nevertheless, this test can be 
also used to detect patients who have IgA antibody deficiency.
Another widely available POCT is Simtomax® Blood Drop system (Augurix SA, 
Switzerland). It is also a lateral flow assay device but slightly more sophisticated as 
it presents with two test line, A and B, in addition to a control line [25]. Test line A 
is used to detect both anti-DGP IgA and IgG antibodies, while test line B is for the 
detection of the whole IgA antibodies. Control line detects the presence of antibod-
ies by capturing with anti-mouse antibodies. On the test line A, synthetic DGP is 
embedded to capture and detect anti-DGP IgA and IgG. For the test line B, mouse 
anti-human IgA detects total IgA. For the conjugate pad, it is secondary antibodies 
combined with gold colloid. If anti-DGP present in the patient’s serum, anti-DGP 
will be captured by the secondary antibodies in the conjugate pad, and then the com-
plex will flow further to the test line A and B, captured by A and B, and line A and B 
will become red. For the control line, goat anti-mouse antibodies are pre-attached; 
Figure 2. 
Scheme of Biocard™ celiac test.
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the excess conjugate of gold colloid with secondary antibodies can interact with it 
forming red line. All these three lines can be formed after 10 minutes, but not later 
than 15 min. Three red lines mean that the patient is celiac disease positive and has 
no IgA deficiency. If only two lines become red, in test line A and control line, then 
it represents that the subject is positive for celiac disease and IgA deficient, while 
two red lines, line B and control line, indicate that the subject is healthy, negative for 
celiac disease, and has IgA deficiency. Only one red line on the control means that 
the subject is negative for celiac disease but positive for IgA deficiency. If all of these 
three lines do not turn red demonstrating a non-valid result, meaning the patient 
needs a further test with a new device.
Various assessments have been done for this commercial kit, and it has been 
proved to have high sensitivity (95–100%) and specificity (93.1–95.7%) [26–28]. 
However, specificity of this test drastically reduced when used for patients on 
a gluten-free diet [26, 29]. This is not surprising as the amount of celiac-related 
antibodies will decrease with a strict following of gluten-free diet but still can be 
present due to unaware consumption of gluten.
Except the above two simple and popular POCT kits, additional lateral flow test 
has made commercially available, Stick CD 1 and 2 [30]. Stick CD 1 can detect IgA, 
IgG, and IgM antibodies against human tTG, while Stick CD 2 also detects AGA 
antibodies. It was demonstrated that the sensitivity of Stick CD 1 was 97% and as to 
CD 2, 95% for anti-tTG antibodies and 63% for AGA antibodies. The specificity of 
CD1 has been shown to reach 99%; as for CD 2, it was 99% for anti-tTG antibodies 
[30].
There are multiple ELISA-based tests that are widely available to identify celiac 
disease, such as Celikey® or QUANTA®. Typically, these kits use ELISA assay to 
detect IgA anti-tTG and/or anti-DPG antibodies. The reported sensitivity and 
specificity have been reported to be higher than 90% [31–33]. QUANTA® products 
have a various series of commercial kits and can detect different biomarkers with 
high sensitivity and specificity for celiac disease detection [34] (Table 1), includ-
ing IgA anti-DGP, IgG anti-DGP, IgA human anti-tTG, IgA, and anti-tTG/DGP 
screening. It can be seen from Table 1 that the performance of traditional ELISA-
based test is still slightly higher than that of any lateral flow tests. This is one of the 
reasons that most of the gastroenterologists have not accepted the use of POCT as 
an alternative to the lab-based tests.
3.2 Research development for point-of-care tests
Although there are some commercial products for the assay of celiac disease 
in the market, the effort has not been stopped to devise a low-cost kit with high 
accuracy. In 2005, Korponay-Szabó et al. developed a POCT that could rapidly 
detect the autoantibodies of tTG from blood sample [35]. The test is based on a 
Test Sensitivity (95% CI) (%) Specificity (95% CI) (%)
IgA DGP 98.4 (91.4–99.7) 92.7 (85.5–97.1)
IgG DGP 95.2 (86.7–99.0) 100.0 (96.2–100.0)
IgA human tTG 95.2 (86.7–99.0) 97.9 (92.8–99.7)
IgA and IgG DGP screen 96.8 (89.0–99.5) 99.0 (94.4–99.8)
tTG/DGP screen 100.0 (94.3–100.0) 92.8 (85.8–97.1)
Table 1. 
Performance of QUANTA lite celiac disease tests in a high-risk population.
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Nunc-Immunostick (Denmark) principle with a four-wing stick. The two wings of 
the stick are pre-covered with gelatine to recognize and capture self-tTG/anti-tTG 
antibody complexes from the hemolyzed patient blood sample. The third wing 
is fixed with anti-human IgA antibodies, to combine with plasma IgA, which is 
used as a positive control. The fourth wing has no coating leading to the absence of 
antibody capture, and it serves as a negative control. In the test process, one drop 
of blood is inserted into the hemolyzing solution and incubated with the stick for 
15 min. Then, the stick is washed with water and immersed for another 15 min in 
the solution of peroxidase-labeled anti-human IgA. To obtain a visible signal, the 
stick is washed again and then inserted into tetramethyl benzidine solution, which 
is used as a color reagent, to observe the color change. If these three wings become 
blue within 5 min, it means that the result is positive for celiac disease. Negative 
result can be confirmed when only the IgA-sensitive part turns blue. If no blue color 
appears, it indicates that the sample was IgA deficient, and the test is invalid. It was 
demonstrated that the sensitivity and specificity were 97.0 and 96.9%, respectively, 
after testing 164 human blood samples of untreated celiac patients [35].
In recent years, another design for POCT device to detect celiac disease has been 
based on electrochemical biosensor. The desirable features of POCT, such as low 
cost and ease of operation, match well with the utilization of electrochemical bio-
sensor [36]. It makes biosensors suitable for the commercial applications. Moreover, 
commercial device to detect blood glucose has been widely used in clinics and 
households, boosting motivation of researchers to devise electrochemical sensors 
for the rapid test of celiac disease.
In 2012, Adornetto et al. developed a novel fast immunosensor to achieve 
anti-tTG antibody detection based on magneto-electrochemistry from serum 
samples [37]. In this system, tTG antigen-coated magnetic beads are used to 
capture and detect antibodies against tTG from positive serum samples. Alkaline 
phosphatase-labeled anti-human IgA antibodies are used as a control. Magnetized 
screen-printed electrodes coupled with a portable instrument serving to read out 
electrochemical signal, which is produced after the addition of α-naphthyl phos-
phate that is enzymatically converted into the electrochemically active α-naphthol 
product. The device was used to analyze 107 blood serum samples (46 positive vs. 
61 negative samples), and it was able to identify with a clinical sensitivity of 100% 
and a specificity of 98.36%, while the cutoff was 1.0 AU/ml. This is comparable to 
spectrophotometric ELISA kits (98.57%, 100%, and 7.00 AU/ml, respectively).
Interestingly, in 2015, Adornetto et al. have engineered another electrochemi-
cal immunoassay system to detect the IgA anti-tTG antibodies [38]. The authors 
described a similar system, but the biggest change was that this device is used for 
the detection of celiac disease in saliva sample with high sensitivity. This is the 
first report that overcomes the problem associated with saliva samples, such as low 
levels of IgA anti-tTG antibodies and high liquid viscosity. In this device, magnetic 
beads were covered with the tTG antigen to react with antibodies against IgA anti-
tTG, which would typically be present in saliva samples of positive celiac disease 
patients. The marker in this case was the conjugate of anti-human IgA and alkaline 
phosphate enzyme. The electrochemical transducer was created with a strip of eight 
magnetized screen-printed electrodes. This device showed the clinical sensitivity of 
95% and specificity of 96% when analyzed in 66 saliva samples. The results show 
the suitability for this POCT as noninvasive screening for celiac disease.
In another study, a modular electrochemical peptide-based sensor was devel-
oped to detect anti-DGP antibody [39]. In this approach, firstly a short helical 
support peptide (SP) was immobilized on the surface of a gold electrode, followed 
by functionalization of SP with DGP and methylene blue (MB), which are used as 
the antigen and electrochemical tag, respectively. When the added anti-DGP IgG 
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monoclonal antibody was recognized and then bound with the DGP, the transfer 
electrons efficiency between DGP and gold surface was reduced, leading to a 
signal decrease in a potentiometer. This unique modular style could guarantee the 
background of high currents when DGP antibody is absent, even at low surface 
densities of DGP. This means that this system could achieve a low-limit detection 
of anti-DGP. Although this system presents a great potential, it was not properly 
assessed on a real human serum or saliva sample from celiac patients. Nevertheless, 
it represents an alternative direction for the future development of POCT device.
A creative electrochemiluminescence immunosensor for the test of tTG was 
designed based on the detection platform of a membrane-templated gold nano-
electrode ensemble [40, 41]. In this platform, tTG antigen was first immobilized on 
the surface of polycarbonate to capture the target anti-tTG antibody present in the 
sample. Then it could react with the biotinylated secondary antibody, which was 
labeled with ruthenium-based electrochemiluminescence reagent modified with 
streptavidin. The application of an oxidizing potential could induce the generation 
of intense and sharp electrochemiluminescence signal, which was used to analyze 
different concentrations of anti-tTG. The result showed that its linear range was 
between 1.5 ng/mL and 10 μg/mL, with a detection limit of 0.5 ng/mL. This system 
was applied to detect human sera samples from five celiac patients and two healthy 
controls as a proof of concept for screening test of celiac disease with great out-
comes. Nevertheless, this test still requires more human samples and more vigorous 
validation for the potential in POCT application.
Recently, our group has developed a novel one-step test for screening celiac 
disease [41]. The test is based on a precipitation principle of gliadin peptide-coated 
gold nanoparticles. In this test, diluted serum is added to the prepared peptide-
coated gold colloids in a small tube. If AGA antibodies are present in serum, it 
causes agglutination of gold colloids and essentially leads to a colloid precipitation. 
The test was used on 30 human serum samples (26 positive celiac samples and 4 
controls) in a blinded assessment. The test demonstrated an overall sensitivity and 
specificity of over 85%, indicating that this assay has potential to be adopted as 
screening tool for celiac disease. Furthermore, this test could be a part of an exclu-
sion-based diagnostic strategy in testing high risk of celiac disease populations.
4. Outlook for the future POCT development
Over the last decade, several POCTs have been introduced to the market, but 
these tests have not been widely accepted by clinicians [42]. Moreover, the 2009 
National Institute for Clinical Excellence (NICE) guideline CG 86 recommended 
that self-tests and/or POCT for celiac disease should not be used as a substitute for 
laboratory-based tests [43]. Therefore, even though the current POCT devices can 
be used to detect celiac disease with a relatively high sensitivity, their specificity 
somewhat lags behind lab-based tests. However, one of the biggest drawbacks of the 
current available POCTs is their lack of usability by a non-trained person.
Most of the lab-based tests for celiac disease are performed by trained clinical 
technicians, but POCTs are generally aimed to be performed by a non-trained 
person. Multiple steps and components, such as blood drawn from a finger prick, 
accurate amount of blood requirement, addition of dilatants or other solutions and 
visual interpretation, would typically introduce user errors leading to a decrease in 
accuracy of the tests. The usability of POCTs has been assessed on the example of 
HIV self-testing kits [44]. In this particular study, authors found that almost 50% 
of the untrained participants performing POCT HIV test had made multiple errors 
during testing. It is clear that for a successful adaptation of POCTs across the globe, 
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ideal self-test kits must include easy-to-understand instructions, preferably one-
step operation and easy-to-interpret results.
As discussed above, most of the POCT systems utilize whole blood or serum 
samples for celiac disease detection. Drawing blood from vein or from finger prick 
can be viewed by some people as invasive and painful leading to a withdrawal 
from voluntary testing. In addition, all the mentioned laboratory or POCTs target 
autoantibodies, such as antibody against tTG, DGP, or even EMA. It means that 
celiac disease can only be detected after antibodies are circulated in the human 
body. However, antibody-based tests generally fail at the latent or silent cases of 
celiac disease or people on voluntary gluten-free diet. Can we achieve celiac disease 
detection when there is a low amount or no antibodies found? Maybe it is another 
challenge that researchers have to face when devising the future screening methods 
and tools for celiac disease.
In other fields of analyte detection, including the detection of blood glucose, on-
site alcohol and illicit drug tests, and confirmation of pregnancy, there are already 
various well-developed and commercialized products from different brands. These 
examples comprise of the use of nanotechnology, microfluidics, or the combination 
of these two methods together that provide some inspiration for future methods 
of POCT for celiac disease. In particular, highly accurate and sensitive fast test of 
HIV [45, 46], tuberculosis [47–49], and malaria [50–52] combine the utilization of 
lateral flow microfluidics with visual colorimetric observation detection. Indeed, 
these POCT diagnostic devices can probably provide the most effective and useful 
tool for mass diagnosis. Additionally, these tests have been proven to be cost-effec-
tive, simple, and portable, as well as with capacity for multiplexing.
5. Conclusion
In conclusion, this chapter has reviewed the current commercially and labora-
tory-based developed POCT devices and the challenges to be faced with for a rapid 
and simple test of celiac disease. It is expected that more efforts of multidisciplinary 
research involved in immunology, lateral flow technology, microfluidics, nanotech-
nology, and genetics could provide a great opportunity for the fast, accurate, and 
early diagnosis of celiac disease, dramatically improving the quality of human life.
Acknowledgements
Dr. Shimoni acknowledges the Australian Research Council, National Health 
and Medical Research Council, and AMP Foundation for financial support 
(APP1101258, IH150100028).
Conflict of interest
Authors declare no conflict of interest.
9© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Challenges with Point-Of-Care Tests (POCT) for Celiac Disease
DOI: http://dx.doi.org/10.5772/intechopen.81874
Author details
Huan Wu1, Michael Wallach2 and Olga Shimoni1*
1 Faculty of Science, Institute for Biomedical Materials and Devices, University of 
Technology Sydney (UTS), Ultimo, New South Wales, Australia
2 Faculty of Science, School of Life Sciences, University of Technology Sydney, 
Ultimo, New South Wales, Australia
*Address all correspondence to: olga.shimoni@uts.edu.au
10
Celiac Disease - From the Bench to the Clinic
[1] Meeuwisse G. Diagnostic criteria 
in coeliac disease. Acta Paediatrica 
Scandinavica. 1970;59:461-463
[2] Kang J et al. Systematic review: 
Worldwide variation in the frequency 
of coeliac disease and changes over 
time. Alimentary Pharmacology & 
Therapeutics. 2013;38(3):226-245
[3] Tonutti E, Bizzaro N. Diagnosis and 
classification of celiac disease and gluten 
sensitivity. Autoimmunity Reviews. 
2014;13(4-5):472-476
[4] Korponay-Szabó IR et al. Population 
screening for coeliac disease in 
primary care by district nurses using 
a rapid antibody test: Diagnostic 
accuracy and feasibility study. BMJ. 
2007;335(7632):1244-1247
[5] Brandtzaeg P et al. Immunobiology 
and immunopathology of human 
gut mucosa: Humoral immunity 
and intraepithelial lymphocytes. 
Gastroenterology. 1989;97(6): 
1562-1584
[6] Mäki M. 3 the humoral immune 
system in coeliac disease. Baillière's 
Clinical Gastroenterology. 
1995;9(2):231-249
[7] Marzari R et al. Molecular dissection 
of the tissue transglutaminase 
autoantibody response in celiac 
disease. The Journal of Immunology. 
2001;166(6):4170-4176
[8] Mawhinney H, Love A. Anti-reticulin 
antibody in jejunal juice in coeliac 
disease. Clinical and Experimental 
Immunology. 1975;21(3):394
[9] Salmi T et al. Immunoglobulin A 
autoantibodies against transglutaminase 
2 in the small intestinal mucosa predict 
forthcoming coeliac disease. Alimentary 
Pharmacology & Therapeutics. 
2006;24(3):541-552
[10] Salmi TT et al. Endomysial 
antibody-negative coeliac disease: 
Clinical characteristics and intestinal 
autoantibody deposits. Gut. 
2006;55(12):1746-1753
[11] Clemente MG et al. Immune 
reaction against the cytoskeleton in 
coeliac disease. Gut. 2000;47(4):520-526
[12] Ngom B et al. Development and 
application of lateral flow test strip 
technology for detection of infectious 
agents and chemical contaminants: A 
review. Analytical and Bioanalytical 
Chemistry. 2010;397(3):1113-1135
[13] Sajid M, Kawde A-N, Daud M.  
Designs, formats and applications of 
lateral flow assay: A literature review. 
Journal of Saudi Chemical Society. 
2015;19(6):689-705
[14] Fasano A, Catassi C. Current 
approaches to diagnosis and treatment 
of celiac disease: An evolving spectrum. 
Gastroenterology. 2001;120(3):636-651
[15] Raivio T et al. Self 
transglutaminase-based rapid coeliac 
disease antibody detection by a lateral 
flow method. Alimentary Pharmacology 
& Therapeutics. 2006;24(1):147-154
[16] Bienvenu F et al. Evaluation 
of a point-of-care test based on 
deamidated gliadin peptides for celiac 
disease screening in a large pediatric 
population. European Journal of 
Gastroenterology & Hepatology. 
2012;24(12):1418-1423
[17] Giersiepen K et al. Accuracy of 
diagnostic antibody tests for coeliac 
disease in children: Summary of an 
evidence report. Journal of Pediatric 
Gastroenterology and Nutrition. 
2012;54(2):229-241
[18] Korponay-Szabó IR. Autoantibodies 
and CD: Past and future of celiac 
antibody testing. Journal of Pediatric 
References
11
Challenges with Point-Of-Care Tests (POCT) for Celiac Disease
DOI: http://dx.doi.org/10.5772/intechopen.81874
Gastroenterology and Nutrition. 
2014;59:S11-S13
[19] Mooney PD et al. Point-of-
care testing for celiac disease has 
a low sensitivity in endoscopy. 
Gastrointestinal Endoscopy. 
2014;80(3):456-462
[20] da Silva Kotze LM et al. A Brazilian 
experience of the self transglutaminase-
based test for celiac disease case finding 
and diet monitoring. World journal of 
gastroenterology: WJG. 2009;15(35):4423
[21] Catassi C, Cobellis G. Coeliac 
disease epidemiology is alive and 
kicking, especially in the developing 
world. Digestive and Liver Disease. 
2007;39(10):908-910
[22] Raivio T et al. Comparison of a novel 
whole blood transglutaminase-based 
ELISA with a whole blood rapid antibody 
test and established conventional 
serological celiac disease assays. Journal 
of Pediatric Gastroenterology and 
Nutrition. 2008;47(5):562-567
[23] Popp A et al. Fingertip rapid point-
of-care test in adult case-finding in 
coeliac disease. BMC Gastroenterology. 
2013;13(1):115
[24] Alarida K et al. Coeliac disease in 
Libyan children: A screening study 
based on the rapid determination of 
anti-transglutaminase antibodies. 
Digestive and Liver Disease. 
2011;43(9):688-691
[25] Mooney PD, Kurien M, Sanders DS. 
Simtomax, a novel point of care test 
for coeliac disease. Expert Opinion on 
Medical Diagnostics. 2013;7(6):645-651
[26] Benkebil F et al. Diagnostic accuracy 
of a new point-of-care screening assay 
for celiac disease. World Journal of 
Gastroenterology: WJG. 2013;19(31):5111
[27] Polanco I et al. Efficacy of a point-
of-care test based on deamidated gliadin 
peptides for the detection of celiac 
disease in pediatric patients. Revista 
Española de Enfermedades Digestivas. 
2017;109(11):743-748
[28] Lau MS et al. The role of an IgA/
IgG-deamidated gliadin peptide point-
of-care test in predicting persistent 
villous atrophy in patients with celiac 
disease on a gluten-free diet. The 
American Journal of Gastroenterology. 
2017;112(12):1859
[29] Mizen L. Simtomax®: A new 
screening tool for coeliac disease. British 
Journal of Healthcare Management. 
2012;18(1):27-32
[30] Khangura J et al. Point-of-care 
testing for coeliac disease: Primary 
care diagnostic technology update. The 
British Journal of General Practice. 
2013;63(611):e426-e428
[31] Fernández E et al. Comparison 
of six human anti-transglutaminase 
ELISA-tests in the diagnosis of celiac 
disease in the Saharawi population. 
World Journal of Gastroenterology: 
WJG. 2005;11(24):3762
[32] Bürgin-Wolff A et al. 
Antibodies against human tissue 
transglutaminase and endomysium 
in diagnosing and monitoring coeliac 
disease. Scandinavian Journal of 
Gastroenterology. 2002;37(6):685-691
[33] Collin P et al. Antiendomysial 
and antihuman recombinant tissue 
transglutaminase antibodies in the 
diagnosis of coeliac disease: A biopsy-
proven European multicentre study. 
European Journal of Gastroenterology 
& Hepatology. 2005;17(1):85-91
[34] Sugai E et al. Celiac disease serology 
in patients with different pretest 
probabilities: Is biopsy avoidable? World 
Journal of Gastroenterology: WJG. 
2010;16(25):3144
[35] Korponay-Szabó IR et al. Coeliac 
disease case finding and diet monitoring 
Celiac Disease - From the Bench to the Clinic
12
by point-of-care testing. Alimentary 
Pharmacology & Therapeutics. 
2005;22(8):729-737
[36] Tüdős AJ, Besselink GA, Schasfoort 
RB. Trends in miniaturized total 
analysis systems for point-of-care 
testing in clinical chemistry. Lab on a 
Chip. 2001;1(2):83-95
[37] Adornetto G et al. An ELIME 
assay for the rapid diagnosis of coeliac 
disease. Analytical and Bioanalytical 
Chemistry. 2012;403(4):1191-1194
[38] Adornetto G et al. An 
electrochemical immunoassay for the 
screening of celiac disease in saliva 
samples. Analytical and Bioanalytical 
Chemistry. 2015;407(23):7189-7196
[39] Puiu M et al. A modular 
electrochemical peptide-based 
sensor for antibody detection. 
Chemical Communications. 
2014;50(64):8962-8965
[40] Habtamu HB et al. A sensitive 
electrochemiluminescence 
immunosensor for celiac disease 
diagnosis based on nanoelectrode 
ensembles. Analytical Chemistry. 
2015;87(24):12080-12087
[41] Kaur A et al. Novel screening test for 
celiac disease using peptide functionalized 
gold nanoparticles. World Journal of 
Gastroenterology. 2018. In press
[42] Kaur A, Shimoni O, 
Wallach M. Celiac disease: From 
etiological factors to evolving 
diagnostic approaches. Journal of 
Gastroenterology. 2017;52(9):1001-1012
[43] National Institute of Health and 
Care Excellence. Coeliac Disease: 
Recognition and Assessment of Coeliac 
Disease. 2009
[44] Peck RB et al. What should the 
ideal HIV self-test look like? A usability 
study of test prototypes in unsupervised 
HIV self-testing in Kenya, Malawi, 
and South Africa. AIDS and Behavior. 
2014;18(4):422-432
[45] Ketema F et al. A 10-minute, 
US Food and Drug Administration-
approved HIV test. Expert 
Review of Molecular Diagnostics. 
2005;5(2):135-143
[46] Greenwald JL et al. A rapid 
review of rapid HIV antibody tests. 
Current Infectious Disease Reports. 
2006;8(2):125-131
[47] Veigas B et al. Gold on 
paper–paper platform for 
Au-nanoprobe TB detection. Lab on a 
Chip. 2012;12(22):4802-4808
[48] Lyashchenko KP et al. PrimaTB 
STAT-PAK assay, a novel, rapid lateral-
flow test for tuberculosis in nonhuman 
primates. Clinical and Vaccine 
Immunology. 2007;14(9):1158-1164
[49] Manabe YC et al. Point-of-care 
lateral flow assays for tuberculosis and 
cryptococcal antigenuria predict death 
in HIV infected adults in Uganda. PLoS 
One. 2014;9(7):e101459
[50] Fu E et al. Two-dimensional  
paper network format that enables 
simple multistep assays for use  
in low-resource settings in the  
context of malaria antigen 
detection. Analytical Chemistry. 
2012;84(10):4574-4579
[51] He L et al. Development of a 
colloidal gold-based lateral flow dipstick 
immunoassay for rapid qualitative and 
semi-quantitative analysis of artesunate 
and dihydroartemisinin. Malaria 
Journal. 2014;13(1):127
[52] Cordray MS, Richards-Kortum RR. 
Emerging nucleic acid-based tests  
for point-of-care detection of 
malaria. The American Journal of 
Tropical Medicine and Hygiene. 
2012;87(2):223-230
